Developing new treatments to combat bacterial resistance using biopharmaceuticals
Official title: Preclinical Services for Antibacterial Resistance Biopharmaceutical Product Development
Funded at Latham Biopharm Group, INC. · NIH-10934793 · Data updated 2026-11-12
This study is working on new treatments to help fight infections caused by bacteria that don't respond to regular medicines, using cutting-edge technology to create helpful products like antibodies and proteins, and it's designed for anyone interested in better options for treating tough infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Latham Biopharm Group, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 8, 2023 |
| Project end | September 7, 2030 |
| Funding year | 2023 |
| Award (this year) | $1,000 |
| NIH project number | 75N93023D00014-0-759302300001-1 |
| Project ID | NIH-10934793 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections that are resistant to standard antibiotic treatments.
✕Less likely to help
Patients with infections that are easily treatable with existing antibiotics may not benefit from this research.
What this research studies
This research focuses on the preclinical development of innovative biopharmaceutical products aimed at addressing bacterial drug resistance. It utilizes advanced biotechnology processes to create materials such as monoclonal antibodies, recombinant proteins, and small interfering RNA (siRNA) vectors. The program includes comprehensive services like product development planning, assay development, and regulatory support to ensure effective translation of these products into clinical applications for infectious diseases.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for infections caused by antibiotic-resistant bacteria.
How similar studies have gone: Other research has shown promise in developing biopharmaceuticals for infectious diseases, indicating that this approach has potential for success.
Where this research is happening
-
Latham Biopharm Group, INC.
Cambridge, United States Active
Related research
Other NIH-funded projects on the same topics.
-
Developing new biopharmaceutical products for infectious diseases
This study is working on improving new treatments, like antibodies and special proteins, to help fight infections, so patients can eventually benefit from better therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.